PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note published on Thursday morning, Benzinga reports. The brokerage currently has a $21.00 target price on the stock.

PDSB has been the topic of several other research reports. Cantor Fitzgerald reissued an overweight rating on shares of PDS Biotechnology in a research note on Thursday, May 9th. B. Riley reduced their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a buy rating on the stock in a research note on Wednesday, June 12th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $16.67.

PDS Biotechnology Stock Down 0.3 %

Shares of NASDAQ:PDSB opened at $3.22 on Thursday. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The company has a 50 day moving average of $3.25 and a 200-day moving average of $4.00. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.56 and a quick ratio of 4.56. The stock has a market cap of $118.11 million, a price-to-earnings ratio of -2.37 and a beta of 1.91.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.07. On average, sell-side analysts forecast that PDS Biotechnology will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Tempus Wealth Planning LLC bought a new position in PDS Biotechnology in the second quarter valued at approximately $55,000. Inspirion Wealth Advisors LLC lifted its stake in PDS Biotechnology by 1.4% in the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after buying an additional 4,917 shares in the last quarter. Vanguard Group Inc. lifted its stake in PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after buying an additional 82,135 shares in the last quarter. Kathleen S. Wright Associates Inc. bought a new position in PDS Biotechnology in the first quarter valued at approximately $28,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of PDS Biotechnology by 530.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock worth $45,000 after purchasing an additional 7,612 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.